Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Merav who wrote (869)	6/3/1998 9:40:00 AM
From: Hope	Read Replies (1) \| Respond to of 1491

US Army Finds Pharmos' Dexanabinol Effective in Treating Damage Caused by Nerve Gas Exposure HUNT VALLEY, Md., June 3 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS - news) announced at the US Army Medical Research Institute of Chemical Defense 1998 Bioscience Review findings by Dr. Gerald P. H. Ballough, Mr. Jeffry S. Forster and Dr. Margaret G. Filbert which suggest that Pharmos Corporation's dexanabinol (HU-211) may be effective in protecting the brain against damage caused by nerve gas exposure. Originally intended to study the neuroprotective effects of dexanabinol on damage caused by seizures, the research demonstrated that administration of dexanabinol five minutes after the onset of nerve gas-induced seizures significantly reduced brain damage, expressed as an area of necrosis in the temporal lobe, by 76% in the laboratory rats studied. From the study, ''it is concluded that HU-211 provides considerable neuroprotection against brain damage resulting from soman-induced seizures, despite having no apparent effect on the seizures themselves.'' Dr. Anat Biegon, Vice President of R&D at Pharmos Corporation, commented, ''dexanabinol could become part of the standard treatment for nerve gas attacks together with atropine. Longterm neural damage resulting from exposure to nerve gas could be minimized with dexanabinol. This drug is a very effective broad range neuroprotectant.'' Dexanabinol is currently in Phase II trials to treat head trauma. Clinical trials to treat stroke are planned. Dexanabinol has a unique mechanism of action and was shown to be effective in animal models of stroke, head trauma and multiple sclerosis. Pharmos Corporation is a pharmaceutical company specializing in the modification of existing molecules to improve their therapeutic index, i.e. reduce undesirable side effects and/or enhance efficacy. This news release contains forward-looking statements that involve risk and uncertainties. The development of the company's products may differ materially from the company's expectations. Among the factors that could result in a materially different outcome are the inherent uncertainties accompanying new product development, action of regulatory authorities and the results of further trials.